Clinical trials referenced in this document:
Documents that mention this clinical trial
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
https://doi.org/10.1007/s00280-020-04184-z
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
https://doi.org/10.1136/ijgc-2020-001277
Funding for this research was provided by:
EMD Serono
Merck KGaA
Article History
Received: 30 April 2020
Accepted: 14 October 2020
First Online: 4 November 2020
Compliance with ethical standards
:
: NT is an employee of Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. MJ was engaged as a consultant by Merck KGaA, Darmstadt, Germany at the time the analysis was performed. MF is an employee of Merck KGaA, Darmstadt, Germany. BH is an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: This article does not contain any studies with animals performed by any of the authors. A human ethics statement is shown in the above Ethical approval section.
: Informed consent was obtained from all individual participants included in the study.